Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Administration of quadruple therapy for seven days as follows:
Bismuth sub citrate (Chemidarou company) 240 mg BID, Levofloxacin (Abidi company) 500 mg daily, Amoxicillin (Chemidarou
Treatment - Drugs
Administration of quadruple therapy for seven days as follows:
Bismuth sub citrate (Chemidarou company) 240 mg BID, Levofloxacin (Abidi company) 500 mg daily, Amoxicillin (Chemidarou company) 1 g B
Administration of quadruple therapy for ten days as follows:
Bismuth sub citrate (Chemidarou company) 240 mg BID, Levofloxacin (Abidi company) 500 mg daily, Amoxicillin (Chemidarou company) 1 g BID
Sponsors
Vince Chancellor for Research Guilan University of Medical Sciences .
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: H. pylori infection has been confirmed in accordance with Urea Breath Test with carbon-13 or 14 or pathology or stool antigen, The patient satisfaction Exclusion criteria: Pregnant and lactating women, Patients with esophageal cancer, Liver cirrhosis, Heart failure; kidney failure, History of seizures, Hematologic diseases; Allergy to drugs, Patients with an incomplete course of treatment; Severe complications; Discontent to treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication of infection. Timepoint: Eight weeks after completion of treatment. Method of measurement: Urea breath test (Carbon 14). | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications. Timepoint: Two weeks after completion of treatment. Method of measurement: According to the case history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJoukar Farahnaz
Guilan Gastrointestinal and Liver Diseases Research Center
Outcome results
None listed